BioNTech settles patent disputes over COVID-19 vaccine royalties, paying $1.26B to NIH and Penn. BioNTech resuelve disputas de patentes sobre regalías de vacunas COVID-19, pagando $1,26B a NIH y Penn.

BioNTech, co-developer of the Pfizer COVID-19 vaccine, has settled disputes over royalties with the US National Institutes of Health (NIH) and the University of Pennsylvania (Penn). BioNTech, co-desarrollador de la vacuna Pfizer COVID-19, ha resuelto disputas sobre regalías con los Institutos Nacionales de Salud de los Estados Unidos (NIH) y la Universidad de Pennsylvania (Penn). BioNTech will pay $791.5 million to NIH and $467 million to Penn. BioNTech pagará $791,5 millones a NIH y $467 millones a Penn. Pfizer will reimburse BioNTech up to $534.5 million of these payments. Pfizer reembolsará a BioNTech hasta $534,5 millones de estos pagos. The settlements include license agreements for future use of the patents involved. Los acuerdos incluyen acuerdos de licencia para el uso futuro de las patentes implicadas.